Makers of Abortion Pill Rush Supreme Court to Halt In-Person Dispensing Rule
The manufacturers of mifepristone, a critical medication abortion drug, have filed an emergency appeal with the U.S. Supreme Court seeking an immediate pause on a recent ruling from the 5th U.S. Circuit Court of Appeals. The appeals court reinstated a national requirement that mifepristone be dispensed only through in-person visits, potentially halting the expanded telehealth access that has been standard since the Covid-19 pandemic.
Danco Laboratories, the drug’s maker, warned the Supreme Court that the 5th Circuit’s decision is causing “immediate confusion and upheaval” nationwide. The company stressed that many patients have prescriptions ready and appointments scheduled but could be blocked from obtaining the medication due to the new in-person mandate. The emergency appeal was filed with Conservative Justice Samuel Alito and asks the court to issue an “administrative stay” to prevent the ruling from going into effect while the case proceeds on the merits.
Access to Abortion Medication Under Immediate Threat Across the U.S.
This urgent legal battle unfolds less than two years after the Supreme Court refused to curb access to mifepristone when faced with a similar challenge, thereby allowing the drug to remain widely available through telemedicine. The new ruling marks a significant rollback, reinstating policies that were dismantled during the pandemic to improve access to abortion care.
Since Roe v. Wade was overturned, many conservative states sharply restricted abortion clinics, making medication abortion – where mifepristone is paired with another drug – the increasingly dominant option. According to research from the Guttmacher Institute, medication abortions accounted for more than 60% of all abortions in the United States in 2026, underscoring the high stakes of this decision for patients nationwide.
The Biden administration finalized regulations last year eliminating the in-person dispensing rule, promoting telehealth as a safe and accessible way to obtain the drug without risking delays in time-sensitive care. However, those protections are now under threat after Louisiana’s lawsuit challenged the federal regulations for undermining its state abortion ban. The 5th Circuit’s ruling sided with Louisiana, blocking the Biden-era rules nationwide.
Mifepristone’s Safety and Public Health Impact Amplify Stakes
Medical experts and regulators consistently affirm mifepristone’s safety. A comprehensive analysis by CNN notes that the drug has fewer reported side effects than common medications like Viagra or penicillin. The drug’s accessibility via telehealth has been critical for women in restrictive states, and sudden changes risk forcing patients into legal and logistical hurdles, or delaying care past safe limits.
“What should a patient do if she cannot obtain an in-person appointment immediately?” wrote Danco’s attorneys in the Supreme Court appeal, highlighting the chaotic impact of the ruling on patients seeking urgent care.
For readers across Alaska and the United States, this case signals a key moment in ongoing national debates over abortion access and telehealth regulations. The Supreme Court’s response will rapidly shape how mifepristone is distributed and who can access reproductive health services in a post-Roe legal landscape.
What to Watch Next
The Supreme Court is now expected to decide quickly whether to halt the 5th Circuit’s rule while it reviews the case. An immediate stay would maintain the current telehealth access to mifepristone programs, providing critical continuity for patients and providers.
As the case develops, policymakers in Alaska and nationwide will be closely monitoring the impact. Medication abortion access remains a frontline issue for many Americans seeking safe, timely options amid shifting legal and political conditions.
